Trial Search Results

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with Epidermolysis Bullosa (EB).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Jean Yuh Tang

Collaborator: Menlo Therapeutics Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: VPD-737
  • Other: Placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Clinical diagnosis of epidermolysis bullosa and pruritus

Exclusion Criteria:

   - Have chronic liver or renal disease

Ages Eligible for Study

13 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Yana Dutt-Singkh
Not Recruiting